Lung Cancer
Commentary
Drugging the undruggable
Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.
News
Quality of life benefit exaggerated in some cancer studies
News
Cancer may increase risk of type 2 diabetes
Study demonstrates elevated risk of developing diabetes for people with lung, pancreatic, breast, brain, urinary tract, or uterine cancers
News
Good chemo vs. bad chemo: When too much is a bad thing
Study questions the use of inpatient chemotherapy pointing to negative outcomes and high mortality among some patients.
Opinion
My picks for best of ASCO 2022
First-line treatment for colorectal cancer, possible new standard of care for breast cancer, and more.
Opinion
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.
Conference Coverage
Promising treatment option for incurable lung cancer described as ‘significant’
Investigators suggest this combo should be standard therapy for NSCLC going forward.
News
Some smokers don’t get lung cancer; genetics might explain it
These people have genes that help limit mutations to DNA that would turn cells malignant and make them grow into tumors.
News
Improved cancer survival in states with ACA Medicaid expansion
The 2-year overall survival increased from 80.6% before the ACA to 82.2% post ACA in expansion states and from 78.7% to 80% in nonexpansion states...
Original Research
Applicability of the USPSTF Lung Cancer Screening Guidelines in a Predominantly Black Veteran Population
This retrospective chart review examined the efficacy of the 2013 United States Preventive Services Task Force lung cancer screening guidelines in...